Jane Street’s Outlook Therapeutics OTLK Stock Holding History

Jane Street’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.46K	Sell	31,400 -8,100	-21%	-$3.5K	﹤0.01%	11344
2025 Q4	$62.4K	Buy	+39,500	New	+$63.1K	﹤0.01%	10418

Other funds holding OTLK

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $126M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NMC

Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Jane Street's OTLK Position: Q1 2026 in Review

Jane Street sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 104,662 shares — an estimated $45.2K sold.

Jane Street first reported a position in OTLK in Q3 2019 and held it in 14 quarters. The position peaked at $165K in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

Jane Street reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 104,662 Outlook Therapeutics shares in Q1 2026, an estimated $45.2K.
Jane Street first reported a position in Outlook Therapeutics in Q3 2019 and held it in 14 quarters.
Jane Street's Outlook Therapeutics position peaked at $165K in Q4 2025.
54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.